HC Wainwright Has Negative Forecast for CGEM Q1 Earnings

Key Points

• HC Wainwright cut its Q1 2027 EPS forecast for Cullinan Therapeutics to a loss of $0.95 per share from $0.77, while maintaining a “Buy” rating and a $35 price target. It projects a $3.89 per-share loss for full-year 2027.
• Analyst sentiment remains generally positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $33.71, despite some sell ratings.
• Cullinan shares opened at $14.95, well below the consensus target, after the company’s latest quarterly loss of $0.81 per share narrowly missed estimates. Institutional investors own 86.31% of the stock, while insiders have recently sold shares.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - HC Wainwright dropped their Q1 2027 earnings per share (EPS) estimates for Cullinan Therapeutics in a note issued to investors on Friday, September 25th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.95) per share for the quarter, down from their prior forecast of ($0.77). HC Wainwright has a "Buy" rating and a $35.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

A number of other brokerages have also commented on CGEM. TD Cowen raised Cullinan Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. BTIG Research restated a "buy" rating and set a $40.00 price objective on shares of Cullinan Therapeutics in a report on Friday. Wall Street Zen lowered Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 13th. Wedbush lifted their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $33.71.

Cullinan Therapeutics Stock Performance

NASDAQ:CGEM opened at $14.95 on Tuesday. The firm's fifty day moving average is $19.72 and its 200-day moving average is $16.71. Cullinan Therapeutics has a 52 week low of $5.68 and a 52 week high of $23.19. The firm has a market cap of $962.18 million, a P/E ratio of -4.82 and a beta of 0.02.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.01).

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. AlphaCentric Advisors LLC boosted its position in shares of Cullinan Therapeutics by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company's stock worth $286,000 after buying an additional 1,094 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Cullinan Therapeutics in the 2nd quarter valued at approximately $25,000. ProShare Advisors LLC raised its stake in Cullinan Therapeutics by 15.3% during the 4th quarter. ProShare Advisors LLC now owns 12,489 shares of the company's stock valued at $129,000 after acquiring an additional 1,661 shares in the last quarter. Allworth Financial LP raised its stake in Cullinan Therapeutics by 152.4% during the 2nd quarter. Allworth Financial LP now owns 2,893 shares of the company's stock valued at $53,000 after acquiring an additional 1,747 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in Cullinan Therapeutics by 160.6% during the 1st quarter. Royal Bank of Canada now owns 4,044 shares of the company's stock worth $58,000 after acquiring an additional 2,492 shares during the period. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cullinan Therapeutics

In related news, insider Jennifer Michaelson sold 30,000 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $20.26, for a total value of $607,800.00. Following the transaction, the insider owned 162,844 shares in the company, valued at approximately $3,299,219.44. This represents a 15.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 46,000 shares of company stock valued at $922,920. 8.60% of the stock is currently owned by insiders.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company's approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.